PT-141 (Bremelanotide) Dosage Guide: Research Protocol & Reconstitution (2026)

# PT-141 (Bremelanotide) Dosage Guide: Research Protocol & Reconstitution (2026)

PT-141 — marketed under the brand name Vyleesi — is the first FDA-approved melanocortin receptor agonist for hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike vasodilator approaches, bremelanotide acts centrally through hypothalamic melanocortin pathways, making it mechanistically unique among approved pharmacotherapies for sexual dysfunction.

This guide covers reconstitution procedures for research-grade material, the subcutaneous injection protocol from clinical trials, dosage parameters established by the pivotal RECONNECT program, timing and storage considerations, and sourcing markers to identify quality-verified research peptides.

For the full mechanistic and pharmacological background, see the companion article: PT-141 (Bremelanotide): Melanocortin Receptor Agonist Research Profile.

> Research Use Only (RUO) Disclaimer: All information in this article is derived from peer-reviewed clinical literature and the FDA-approved Vyleesi prescribing information. Content is provided for educational and research purposes only. It does not constitute medical advice and should not be used to guide personal treatment decisions. Always consult a licensed healthcare provider.

---

What Is PT-141 (Bremelanotide)?

Bremelanotide is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (α-MSH) with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. It functions as a non-selective melanocortin receptor agonist with highest affinity for MC3R and MC4R subtypes expressed in limbic and hypothalamic regions that regulate sexual arousal and motivation.

Key identifiers:

• •INN: Bremelanotide
• •Research name: PT-141
• •Brand name: Vyleesi (AMAG Pharmaceuticals, now Palatin Technologies/AMAG)
• •FDA approval date: June 21, 2019
• •CAS number: 189691-06-3
• •Molecular formula: C₅₀H₆₈N₁₄O₁₀
• •Molecular weight: 1,025.17 g/mol
• •Receptor targets: MC1R, MC3R, MC4R (primary)

PT-141 originated from Melanotan II research in the 1990s, when clinical volunteers using sunless tanning formulations unexpectedly reported spontaneous sexual arousal. Investigators at the University of Arizona isolated the sexual activity component and developed a more selective analogue — bremelanotide — that ultimately advanced through FDA approval.

FDA indication: Hypoactive sexual desire disorder (HSDD) in premenopausal women who do not have a co-existing sexual dysfunction or medical or psychiatric condition that better accounts for the disorder.

---

Reconstitution of Research-Grade PT-141

The FDA-approved Vyleesi product is supplied as a pre-filled 1.75 mg/0.3 mL auto-injector containing ready-to-use solution. Research-grade bremelanotide, however, is typically supplied as lyophilized (freeze-dried) powder that must be reconstituted before use.

Solvent Selection

Bacteriostatic water for injection (0.9% benzyl alcohol in sterile water) is the standard reconstitution vehicle for research-grade peptides including bremelanotide. Benzyl alcohol inhibits microbial contamination and extends the usable shelf life of reconstituted solutions compared to sterile water alone.

Alternative solvents used in some research contexts:

• •Sterile water for injection (SWFI): Acceptable for immediate use; no preservative, so reconstituted solution must be used within 24 hours
• •Acetic acid (0.5%): Used for peptides that do not dissolve readily in neutral water; less common for bremelanotide given its favorable solubility profile

Target Concentration

Research-grade bremelanotide is most commonly reconstituted to concentrations of 1.75–3.5 mg/mL, matching the clinical dose in a 0.5–1.0 mL injection volume:

Step-by-Step Reconstitution Protocol

1. Equilibrate the vial: Allow the sealed lyophilized vial to reach room temperature (~15 minutes) before opening. This minimizes thermal stress on the peptide.

2. Sanitize: Wipe the rubber stopper with a 70% isopropyl alcohol swab. Allow it to air-dry for 30 seconds.

3. Draw solvent: Using a sterile 1 mL insulin syringe or a low-dead-volume syringe, draw the calculated volume of bacteriostatic water.

4. Inject solvent slowly: Insert the needle at an angle and inject the solvent slowly down the side wall of the vial — not directly onto the powder cake. This prevents foaming and denaturation.

5. Dissolve gently: Gently swirl (do not shake) until the powder is fully dissolved. The solution should appear clear and colorless. Any particulate matter or cloudiness warrants discarding the vial.

6. Label and date: Mark the vial with the reconstitution date, concentration, and expiry (28 days from reconstitution if using bacteriostatic water; 24 hours if using plain SWFI).

Quality Verification Before Use

Before drawing a dose, visually inspect the reconstituted solution for:

• •Cloudiness or turbidity
• •Visible particulates
• •Off-coloration (should be clear, not yellow or amber)
• •Precipitation at the vial base

Discard the vial if any of these signs are present.

---

Administration: Subcutaneous Injection Protocol

Bremelanotide is administered via subcutaneous (SC) injection — not intravenous or intramuscular. This route was used consistently across all pivotal clinical trials and is specified in the FDA-approved label.

Injection Sites

Approved injection sites (per Vyleesi prescribing information):

• •Abdomen: At least 2 inches (5 cm) from the navel; avoid areas with scars, bruising, or sensitivity
• •Thigh: Outer (lateral) aspect of the upper thigh

Site rotation is recommended to minimize local tissue irritation, particularly if the compound is used more than once in a week.

Injection Technique

1. Prepare the injection site: Wipe a circular area (~5 cm diameter) with an alcohol swab and allow to dry

2. Pinch and elevate the skin: Gently pinch a fold of skin between the thumb and forefinger to lift subcutaneous tissue away from underlying muscle

3. Insert at 45–90°: A 45° angle is preferred for individuals with lower adipose tissue; 90° is acceptable with adequate SC tissue

4. Inject slowly: Depress the plunger steadily over 5–10 seconds

5. Withdraw and apply pressure: Remove the needle at the same angle of insertion; apply light pressure with a clean swab (do not rub)

6. Safe needle disposal: Cap and dispose of needles in a puncture-resistant sharps container

Vyleesi Auto-Injector (Commercial Product)

The Vyleesi device is a single-use auto-injector pre-loaded with 1.75 mg/0.3 mL. Users press the device against the skin and activate with a button; the needle deploys, injects the full dose, and retracts automatically. No drawing or preparation is needed.

---

Dosage Range: Clinical Research and FDA Approval Data

The Established Research Dose

The 1.75 mg subcutaneous dose is the only dose that has been validated in Phase 3 clinical trials and appears in the FDA-approved prescribing information. No peer-reviewed randomized controlled trial has established efficacy or safety for doses above or below 1.75 mg in the context of HSDD.

Phase 3 data source: RECONNECT-1 (NCT02333071) and RECONNECT-2 (NCT02338960) — two parallel, randomized, double-blind, placebo-controlled trials enrolling 1,247 premenopausal women aged 22–55 years with generalized acquired HSDD.

FDA-Approved Label Dosing Summary

Efficacy Summary from Pivotal Trials

From Kingsberg et al. (2019) [PMID: 31599840]:

• •Statistically significant improvement in satisfying sexual events (SSEs) vs. placebo in RECONNECT-1
• •Significant reduction in sexual distress score (FSDS-DAO item 13) across both trials
• •Effect size was modest but clinically meaningful for a disorder with limited pharmacotherapy options
• •No evidence that higher doses produce superior efficacy — 1.75 mg represents the optimized dose from Phase 2 development

Early-Phase Dose Exploration

Phase 1 and 2 trials explored a broader dose range (0.3–7.5 mg), with the 1.75 mg dose selected based on the benefit-risk profile:

• •Lower doses (0.3–0.75 mg): Subtherapeutic response
• •1.75 mg: Optimal efficacy-to-tolerability ratio
• •Higher doses (≥3 mg): Increased nausea, flushing, and transient blood pressure elevation without proportional efficacy gain

Label restriction: No more than 1 dose per 24-hour period.

---

Timing Considerations: Pre-Administration Window

The pre-administration timing of bremelanotide is clinically important because the compound must reach relevant CNS targets before its desired effect is needed.

FDA Label Guidance

The approved label specifies administration at least 45 minutes before anticipated sexual activity. This window reflects the pharmacokinetic profile of bremelanotide:

• •Tmax (time to maximum plasma concentration): ~1 hour after SC injection
• •Onset of CNS activity: Consistent with the 45-minute pre-administration guideline
• •Duration of effect: Plasma half-life is approximately 2.7 hours; subjective effects in clinical trials typically persisted for 2–4 hours post-administration

Clinical Trial Timing Protocol

In the RECONNECT trials, participants were instructed to self-administer the study drug approximately 45 minutes before anticipated sexual activity. The flexible on-demand design allowed use up to 8 times per month in the trial period, with no restriction on minimum interval beyond the 24-hour maximum.

Practical Research Timing Notes

• •Effects typically begin to manifest 30–60 minutes post-injection
• •Peak plasma exposure at ~60 minutes post-injection
• •Blood pressure elevations (which can occur) typically peak within 1–2 hours and resolve by 6–8 hours
• •The 24-hour re-dosing restriction relates to the blood pressure safety profile, not to receptor kinetics

---

Storage After Reconstitution

Storage conditions affect peptide stability and are critical for maintaining research integrity.

Lyophilized (Unreconstituted) Material

Store lyophilized vials in the original sealed vial with desiccant. Do not open until ready for reconstitution.

Reconstituted Solution

Handling principles:

• •Never freeze reconstituted bremelanotide — freezing can cause peptide aggregation and loss of potency
• •Minimize light exposure; store in amber vials or wrapped in foil where possible
• •Do not use if the solution has been left at room temperature for extended periods

---

Sourcing and Quality Markers for Research-Grade PT-141

Quality control for research peptides is especially important when the compound will be used in controlled studies. The research peptide market is largely unregulated, and significant variability in purity, potency, and sterility exists between suppliers.

Essential Quality Certifications

High-Performance Liquid Chromatography (HPLC) purity report: The primary purity assay for research peptides. Research-grade bremelanotide should be ≥98% purity by HPLC. Request the actual chromatogram, not just a stated percentage.

Mass spectrometry (MS) identity confirmation: Confirms that the peptide delivered matches the intended molecular weight and sequence. Acceptable results should show the correct m/z values for bremelanotide (C₅₀H₆₈N₁₄O₁₀, MW 1025.17).

Certificate of Analysis (CoA): A batch-specific document from the manufacturer that includes HPLC purity, MS confirmation, appearance, solubility, and water content (Karl Fischer method).

Additional Quality Markers

• •Sterility testing: Particularly important if the material will be reconstituted for injection-based studies
• •Endotoxin testing (LAL assay): Critical for injectable applications — high endotoxin loads can confound research outcomes
• •Peptide content / counterion specification: Pure peptide content may differ from nominal weight due to trifluoroacetate or acetate counterions from synthesis; quality suppliers specify the counterion type

Red Flags to Avoid

• •No CoA or only a generic certificate not batch-specific
• •HPLC purity below 95% for research applications
• •No mass spectrometry confirmation
• •Pricing significantly below market average (may indicate diluted or counterfeit material)
• •No physical address or transparent laboratory provenance

Supplier Price Comparison

Use our comparison platform to evaluate PT-141 research-grade suppliers side by side — pricing, purity tiers, quantity options, and CoA availability:

Compare PT-141 supplier prices on Peptides.SO →

This tool lets you filter by purity guarantee, vial size, and independent testing verification to find the best value for your research program.

---

Safety Profile: Key Findings from Clinical Data

Understanding the adverse event profile from Phase 3 trials is essential context for any research using bremelanotide.

Most Common Adverse Events (≥10% incidence, RECONNECT trials)

Nausea is the most commonly reported adverse effect and is typically mild-to-moderate, transient (peaking 30–60 minutes post-injection), and self-resolving. In trials, approximately 13% of bremelanotide users discontinued due to adverse events (versus 2% for placebo), with nausea being the primary driver.

Cardiovascular Considerations

Bremelanotide causes transient, dose-related increases in blood pressure and reductions in heart rate:

• •Mean systolic blood pressure increase: ~4.6 mmHg at 1 hour post-dose
• •Typically resolves within 12 hours
• •Contraindicated in patients with known cardiovascular disease or uncontrolled hypertension per FDA label
• •Blood pressure should return to baseline before engaging in activity

Hyperpigmentation

Focal hyperpigmentation (darkening) of the face, gums, and breasts has been reported with repeated use. This effect is linked to MC1R agonism and is dose-dependent. The FDA label includes this as a known risk.

---

Regulatory Context and Research Considerations

Bremelanotide is a DEA Schedule V controlled substance in the United States under the Controlled Substances Act (21 C.F.R. §1308.15), reflecting its FDA approval and potential for misuse. This scheduling is distinct from the Schedule I/II designation of unapproved research compounds.

Implications for research:

• •Institutional Review Board (IRB) approval is required for any human research involving bremelanotide
• •Research institutions must comply with applicable controlled substance regulations for procurement, handling, and record-keeping
• •Off-label use or off-protocol investigation requires appropriate oversight structures

All research involving bremelanotide should be conducted under appropriate institutional approval with qualified personnel following good laboratory practice (GLP) guidelines.

---

Summary: PT-141 Research Protocol at a Glance

---

PT-141 vs PDE5 Inhibitors: A Mechanistic Comparison

Understanding how PT-141 (bremelanotide) differs from phosphodiesterase type 5 (PDE5) inhibitors — sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra) — is fundamental for evaluating its research applications, particularly in contexts where PDE5 inhibitors are insufficient or contraindicated.

Central vs. Peripheral Mechanism

Why This Distinction Matters in Research

PDE5 inhibitors require an intact vascular response and underlying arousal — they enhance the physical execution of sexual function but do not address desire or motivation deficits. Bremelanotide, by contrast, operates upstream in the CNS arousal pathway, making it potentially relevant in research contexts involving:

• •Hypoactive sexual desire disorder (HSDD) — where desire itself is absent, not physical function
• •Psychogenic sexual dysfunction — where CNS dysregulation underlies dysfunction
• •Research into melanocortin pathways — independent of vascular mechanisms

This central mechanism also explains why bremelanotide carries a distinct adverse event profile (nausea, transient hypotension from CNS outflow) compared to the peripheral vasodilatory effects of PDE5 inhibitors.

---

PT-141 vs Melanotan II: Differentiation for Researchers

PT-141 (bremelanotide) was derived from Melanotan II (MT-II) research in the early 1990s. Understanding their relationship is important for researchers reviewing the historical literature and for evaluating which compound is appropriate for a given research program.

> Platform Policy Note: Melanotan II is not listed as an active research peptide on this platform. The information below is provided strictly for educational context — to distinguish PT-141's pharmacological profile from its historical precursor. No sourcing information for MT-II is provided.

Historical Relationship

Melanotan II is a synthetic analogue of alpha-MSH developed at the University of Arizona in the late 1980s for its potential as a sunless tanning agent. In early human studies, an unexpected finding emerged: subjects reported spontaneous, prolonged erections and increased sexual arousal. Researchers identified that these effects were mediated through melanocortin MC4R activation.

From this observation, a more targeted compound was developed by removing the tanning activity while retaining and refining the MC4R-mediated arousal effect — this compound became bremelanotide (PT-141), which successfully advanced through FDA approval.

Key Pharmacological Differences

Research Implications

For researchers studying melanocortin pathways in sexual function, PT-141 is the appropriate reference compound because:

1. It has characterized pharmacokinetics and a validated dose (1.75 mg SC)

2. Its safety profile is documented through controlled clinical trials and FDA post-market surveillance

3. Its CNS selectivity is better understood than MT-II's broader receptor engagement

For researchers reviewing older literature that cites Melanotan II as a precursor in mechanistic pathway studies, the relevant modern analog with regulatory acceptance is bremelanotide.

---

Sourcing Research-Grade PT-141

Researchers sourcing bremelanotide for laboratory applications can find verified suppliers — including CoA documentation, HPLC purity reports, and mass spectrometry identity confirmation — on the PT-141 peptide page.

When evaluating dosage calculations for research protocols, the Peptide Dosage Calculator provides a useful reference for working out reconstitution volumes based on vial amount and target dose.

---

References

1. Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder. Obstet Gynecol. 2019;134(5):899-908. PMID: 31599840

2. FDA. Vyleesi (bremelanotide) Prescribing Information. AMAG Pharmaceuticals, Inc. 2019 (revised 2024).

3. Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med. 2006;3(4):628-638.

4. Portman DJ, Brown L, Yuan J, Kissling R, Kingsberg SA. Bremelanotide for hypoactive sexual desire disorder in premenopausal women: analysis of the RECONNECT studies. J Womens Health (Larchmt). 2017;26(2):135-145.

5. Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102.

---

This article is for research and educational purposes only. Bremelanotide (PT-141/Vyleesi) is an FDA-approved prescription medication. Research involving this compound in humans requires IRB oversight and appropriate regulatory compliance. Nothing in this guide constitutes medical advice or a recommendation for personal use.